Table 3: Integrin (signaling) inhibitors in anticancer therapy.

CompoundSponsorTargetCancer typeStage

Vitaxin/etaracizumabMedImmune Inc., NCI v 3Solid tumors, melanoma, colorectal cancer, small intestine cancer, lymphoma, prostate cancer, and renal cell cancerPhase I, II
CTNO 95Centocor Inc. v integrinsSolid tumors, melanoma, and prostate cancerPhase I, II
Cilengitide (cyclic RGD)EMD Pharmaceuticals, Merck v 3, v 5Lung cancer, prostate cancer, melanoma, glioblastoma, leukemia, brain and CNS tumors, breast cancer, and squamous cell cancerPhase I, II
VolociximabProtein
Design Labs
5 1Solid tumors, melanoma, ovarian cancer, renal cancer, pancreatic cancer, and lung cancerPhase I, II
ATN-161 PHSRN mimeticAttenuon 5 1 and other fibronectin-binding integrinsSolid tumors, renal cell carcinoma, and brain and CNS tumorsPhase I
PF-00562271Verastem Inc.FAK, Pyk2Head and neck cancer, prostate cancer, and pancreatic cancerPhase I
GSK2256098GlaxoSmithKlineFAK, Pyk2Solid tumorsPhase I
PF-04554878Verastem Inc.FAK, Pyk2Metastatic, nonhematologic tumorsPhase I
VS-4718Verastem Inc.FAK, Pyk2Metastatic, nonhematologic tumorsPhase I
VS-6063Verastem Inc.FAK, Pyk2Ovarian cancerPhase I